Goto T - Search Results

1

Large isoform of hepatitis delta antigen activates serum response factor-associated transcription.

Goto T, Kato N, Ono-Nita SK, Yoshida H, Otsuka M, Shiratori Y, Omata M. Goto T, et al. J Biol Chem. 2000 Dec 1;275(48):37311-6. doi: 10.1074/jbc.M002947200. J Biol Chem. 2000. PMID: 10961986 Free article.

2

Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability.

Otsuka M, Kato N, Lan K, Yoshida H, Kato J, Goto T, Shiratori Y, Omata M. Otsuka M, et al. Among authors: goto t. J Biol Chem. 2000 Nov 3;275(44):34122-30. doi: 10.1074/jbc.M000578200. J Biol Chem. 2000. PMID: 10924497 Free article.

3

Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer.

Kato N, Yoshida H, Ono-Nita SK, Kato J, Goto T, Otsuka M, Lan K, Matsushima K, Shiratori Y, Omata M. Kato N, et al. Among authors: goto t. Hepatology. 2000 Aug;32(2):405-12. doi: 10.1053/jhep.2000.9198. Hepatology. 2000. PMID: 10915750

4

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. Ono SK, et al. Among authors: goto t. J Clin Invest. 2001 Feb;107(4):449-55. doi: 10.1172/JCI11100. J Clin Invest. 2001. PMID: 11181644 Free PMC article.

5

Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors.

Ohki T, Tateishi R, Goto E, Sato T, Masuzaki R, Imamura J, Goto T, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M. Ohki T, et al. Among authors: goto t, goto e. J Viral Hepat. 2010 Feb 1;17(2):91-7. doi: 10.1111/j.1365-2893.2009.01152.x. Epub 2009 Jun 28. J Viral Hepat. 2010. PMID: 19566786

6

Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH.

Ohki T, Tateishi R, Shiina S, Goto E, Sato T, Nakagawa H, Masuzaki R, Goto T, Hamamura K, Kanai F, Yoshida H, Kawabe T, Omata M. Ohki T, et al. Among authors: goto t, goto e. Gut. 2009 Jun;58(6):839-44. doi: 10.1136/gut.2008.164053. Epub 2009 Jan 27. Gut. 2009. PMID: 19174415

7

Hypercholesterolemic effect in rats of a dietary addition of the nitric oxide synthase inhibitor, L-N omega nitroarginine, by less synthesis of bile acids.

Khedara A, Goto T, Kayashita J, Kato N. Khedara A, et al. Among authors: goto t. Biosci Biotechnol Biochem. 1998 Apr;62(4):773-7. doi: 10.1271/bbb.62.773. Biosci Biotechnol Biochem. 1998. PMID: 9614708 Free article.

8

Quantum dot as a drug tracer in vivo.

Manabe N, Hoshino A, Liang YQ, Goto T, Kato N, Yamamoto K. Manabe N, et al. Among authors: goto t. IEEE Trans Nanobioscience. 2006 Dec;5(4):263-7. doi: 10.1109/tnb.2006.886569. IEEE Trans Nanobioscience. 2006. PMID: 17181025

9

Elevated body fat in rats by the dietary nitric oxide synthase inhibitor, L-N omega nitroarginine.

Khedara A, Goto T, Morishima M, Kayashita J, Kato N. Khedara A, et al. Among authors: goto t. Biosci Biotechnol Biochem. 1999 Apr;63(4):698-702. doi: 10.1271/bbb.63.698. Biosci Biotechnol Biochem. 1999. PMID: 10361682 Free article.

10

Feeding the nitric oxide synthase inhibitor L-N(omega)nitroarginine elevates serum very low density lipoprotein and hepatic triglyceride synthesis in rats.

Goto T, Ohnomi S, Khedara A, Kato N, Ogawa H, Yanagita T. Goto T, et al. J Nutr Biochem. 1999 May;10(5):274-8. doi: 10.1016/s0955-2863(99)00008-x. J Nutr Biochem. 1999. PMID: 15539300

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,590 results

Search Page

Filters